New-onset refractory status epilepticus (NORSE) is characterized by new-onset refractory seizures in patients without prior epilepsy or clear acute structural, toxic, or metabolic causes, often requiring early aggressive immunotherapy and continuous intravenous anesthetic agents to improve outcomes.